Abstract 1557P
Background
Liver metastasis (LM) frequently occurs in patients with advanced gastric cancer; yet our understanding of the underlying salient biology is preliminary. Here, we performed single-cell RNA-seq in two patients with LM of gastric cancer to explore the initiating liver metastasis cells and liver metastatic microenvironment in gastric cancer.
Methods
Single cell RNA sequencing was performed on tissues from LM of gastric cancer. Also, we downloaded the single-cell RNA-seq of hepatocellular carcinoma (HCC) and primary gastric cancer from GEO database. Seurat were applied to sort single-cell RNA-seq of LM in gastric cancer and primary gastric cancer into different clusters via feature dimension reduction and then we investigated their expression profiling, stemness initiating and enrichment pathways. Furthermore, CellChat and monocle2 were used to explore the cellular communication and regulatory network of liver metastatic microenvironment.
Results
The transcriptomes of 13305, 26373, 20207 single cells among LM of gastric cancer, HCC, and primary gastric cancer were extracted respectively. There were 14 clusters divided into epithelial cells of liver metastasis single cells. Differential gene analyses and ratio analyses in LM and corresponding primary cancers groups showed that C10 and C12 might be the LM initiating cells clusters. And they were both enriched in the positive regulation of cell migration. SOX6+ MMP7+ epithelial cells might be the LM initiating cells in gastric cancer. Cell communication and inverse temporal analysis showed that SEPP1+ macrophage and CXCL2+ cancer associated fibroblasts (CAFs) might regulate metastatic microenvironment, of which promoted cancer stem cells migration.
Conclusions
The initiating liver metastasis cells and liver metastatic microenvironment in gastric cancer have been investigated in this study, which provided a further understanding of the potential biological mechanisms of LM in gastric cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1508TiP - The 1920-EORTC-BIORADON study: Molecular characterization of non-small cell lung cancer (NSCLC) and indoor radon exposure in Europe
Presenter: Laura Mezquita
Session: Poster session 21
1509TiP - The 1825-EORTC, ALKALINE: Activity of lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with second generation ALK inhibitor
Presenter: Laura Mezquita
Session: Poster session 21
1510TiP - Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant non-small cell lung cancer (NSCLC) according to TP53 mutational status (TEMPLE-2/NCT05785208)
Presenter: Antonio Vitale
Session: Poster session 21
1515P - Maintenance rucaparib after first-line platinum-based chemotherapy in advanced esophagogastric (OG) adenocarcinoma: Interim results from the PLATFORM trial
Presenter: Anderley Gordon
Session: Poster session 21
1518P - Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a phase Ib/II study
Presenter: Keun-Wook Lee
Session: Poster session 21
1520P - Perioperative treatment in resectable gastric cancer with spartalizumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): The GASPAR phase II trial
Presenter: Melanie Dos Santos
Session: Poster session 21